(Total Views: 746)
Posted On: 01/28/2022 7:06:07 PM
Post# of 72440
Posted by Call Me Crazy ..........on the other board, date published Jan 25th 2022
Small molecular antivirals needed to combat the pandemic
Quote:
Currently, two mRNA vaccines are authorized for COVID-19:
BNT162b2 (Pfizer, Inc., and BioNTech) and mRNA-1273 (ModernaTX, Inc.), and a third single-dose COVID-19 vaccine from Janssen Pharmaceuticals (Johnson and Johnson) was issued for Emergency Use Authorization Although vaccine continues to be a mainstay for viral prophylaxis, the efficacy of vaccine might be compromised with emerging variants such as the delta variant 6-8. For this reason, small molecular antiviral drugs are important complements of vaccines to help combat pandemics...
In summary, our results indicate that brilacidin has a dual antiviral
mechanism of action including targeting host cell surface HSPGs to block viral attachment and inactivating viral particles. This dual antiviral mechanism of action might slow down the pace of resistance development. Taken together, the broad-spectrum antiviral activity of brilacidin against coronaviruses and the previously reported immunomodulatory effect and antibacterial activity warrants its further development as a broad-spectrum antiviral for the treatment of not only current COVID-19 but also future emerging coronaviruses.
https://onlinelibrary.wiley.com/doi/pdf/10.1002/jmv.27616
Small molecular antivirals needed to combat the pandemic
Quote:
Currently, two mRNA vaccines are authorized for COVID-19:
BNT162b2 (Pfizer, Inc., and BioNTech) and mRNA-1273 (ModernaTX, Inc.), and a third single-dose COVID-19 vaccine from Janssen Pharmaceuticals (Johnson and Johnson) was issued for Emergency Use Authorization Although vaccine continues to be a mainstay for viral prophylaxis, the efficacy of vaccine might be compromised with emerging variants such as the delta variant 6-8. For this reason, small molecular antiviral drugs are important complements of vaccines to help combat pandemics...
In summary, our results indicate that brilacidin has a dual antiviral
mechanism of action including targeting host cell surface HSPGs to block viral attachment and inactivating viral particles. This dual antiviral mechanism of action might slow down the pace of resistance development. Taken together, the broad-spectrum antiviral activity of brilacidin against coronaviruses and the previously reported immunomodulatory effect and antibacterial activity warrants its further development as a broad-spectrum antiviral for the treatment of not only current COVID-19 but also future emerging coronaviruses.
https://onlinelibrary.wiley.com/doi/pdf/10.1002/jmv.27616
(8)
(2)Scroll down for more posts ▼
